title: Live attenuated herpes zoster vaccine for HIV-infected adults.
abstract: OBJECTIVE
  Multiple guidelines exist for the use of live viral vaccines for measles-mumps-rubella (MMR), varicella and yellow fever in people with HIV infections, but these guidelines do not make recommendations regarding live attenuated herpes zoster vaccine (LAHZV), which is approved for people over 50 years in the general population. LAHZV is made with the same virus used in varicella vaccine. The incidence of herpes zoster remains increased in people with HIV infection, even when on suppressive antiretroviral therapy, and a growing proportion of HIV-infected patients are over 50 years of age. The purpose of this article is to review the use of varicella vaccine and LAHZV in people with HIV infection and to make recommendations about the use of LAHZV in adults with HIV infection.
  
  
  METHODS
  A PubMed search was undertaken using the terms 'herpes zoster AND HIV' and 'varicella AND HIV'. Reference lists were also reviewed for pertinent citations.
  
  
  RESULTS
  Varicella vaccine is recommended in varicella-susceptible adults, as long as they have a CD4 count > 200 cells/μL, the same CD4 threshold used for MMR and yellow fever vaccines. No transmission of vaccine strain Varicella zoster virus has been documented in people with HIV infections with a CD4 count above this threshold. LAHZV was administered to 295 HIV-infected adults with a CD4 count > 200 cells/μL, and was safe and immunogenic with no cases of vaccine strain infection.
  
  
  CONCLUSIONS
  It is recommended that LAHZV be administered to HIV-infected adults with a CD4 count above 200 cells/μL, the same CD4 threshold used for other live attenuated viral vaccines.
authors: Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, AB, Canada.
authors: S D
authors: SD
authors: Shafran
mesh_terms: D018791:CD4 Lymphocyte Count; D002986:Clinical Trials as Topic; D015658:HIV Infections / Q000150:complications / Q000276:immunology*; D006562:Herpes Zoster / Q000517:prevention & control*; D053061:Herpes Zoster Vaccine / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D017410:Practice Guidelines as Topic; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D053061:Herpes Zoster Vaccine
keywords: HIV infection; adult immunization; herpes zoster